Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29927632 | 0.78 | CA2 (0.41) | CA2NR1I2HSD11B1EPHX2NR1H4 | |
| SCHEMBL19507908 | 0.78 | CA2 (0.41) | CA2NR1I2HSD11B1EPHX2NR1H4 | |
| SCHEMBL22013719 | 0.75 | AKR1C3 (0.34) | CA2KCNN4NR1I2HSD11B1EPHX2 | |
| SCHEMBL20914725 | 0.75 | ALDH1A1 (0.49) | ALDH1A1CA2NPC1NR1I2HSD11B1 | |
| SCHEMBL20914730 | 0.73 | ALDH1A1 (0.44) | ALDH1A1NPC1LMNAKCNN4NR1I2 | |
| SCHEMBL20698926 | 0.73 | CA2 (0.34) | CA2NR1I2HSD11B1EPHX2NR1H4 | |
| SCHEMBL28282284 | 0.73 | LMNA (0.46) | ALDH1A1NPC1LMNAHSD11B1 | |
| SCHEMBL20914717 | 0.72 | ALDH1A1 (0.50) | ALDH1A1CA2NPC1LMNAHSD11B1 | |
| SCHEMBL22011829 | 0.72 | EPHX2 (0.35) | CA2NR1I2HSD11B1EPHX2NR1H4 | |
| SCHEMBL26012999 | 0.72 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD11B1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ALDH1A1 2176/4885CA2 1296/4885NPC1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.